Discover 3,564 paid clinical trials in Costa Mesa, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,564
Patient-Derived Xenografts to Reduce Cancer Health Disparities
for
Bladder Carcinoma, Gastric Carcinoma,
Location: Orange CA, Sacramento CA
Sponsor: University of California, Davis
Sex: All
Age: 21 - 70+
Code: NCT04410302
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: Los Angeles CA, Houston TX, Grand Rapids MI,
Sponsor: Tanabe Pharma America, Inc.
Sex: All
Age: 18+
Code: NCT06943521
Phase1, Phase2, Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Location: Los Angeles CA, Las Vegas NV, Phoenix AZ, Gilbert AZ,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06119581
Phase3, Recruiting
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
for
Oropharyngeal Cancer, Carcinoma
Location: Torrance CA, Beverly Hills CA, Los Angeles CA,
Sponsor: Zachary Zumsteg
Sex: All
Age: 18+
Code: NCT06445114
Phase2, Recruiting
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
for
Malignancy
Location: Burbank CA, Loma Linda CA, Arroyo Grande CA, Pahrump NV,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 0+
Code: NCT04242095
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
for
Nonmuscle-invasive Bladder Cancer
Location: Los Angeles CA, Queen Creek AZ, Cincinnati OH,
Sponsor: ImmVira Pharma Co. Ltd
Sex: All
Age: 18+
Code: NCT06971614
Phase2, Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML